Lilly Gains in Obesity Race With Novo as Supplies Expand
- Lilly lifts 2024 sales view by $3 billion on weight-loss drugs
- Zepbound quarterly sales of $1.2 billion surpass estimates
This article is for subscribers only.
Eli Lilly & Co. is narrowing the gap with rival Novo Nordisk A/S in the race to dominate the red-hot obesity market as it expands its supplies of weight-loss drugs.
Sales of the blockbuster Zepbound were $1.2 billion in the second quarter, Lilly said in a statement, smashing Wall Street’s estimates of $819 million. The company now expects full-year revenue of $45.4 billion to $46.6 billion, up from its earlier guidance that topped out at $43.6 billion.